Handelsbanken Fonder Ab Biocryst Pharmaceuticals Inc Transaction History

Handelsbanken Fonder Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$4.98 - $6.77 $51,792 - $70,408	10,400 Added 29.3%	45,900 $275,000
Q4 2022 Feb 07, 2023	BUY	$10.5 - $14.2 $88,200 - $119,280	8,400 Added 31.0%	35,500 $408,000
Q3 2022 Oct 27, 2022	SELL	$10.79 - $14.81 $92,793 - $127,366	-8,600 Reduced 24.09%	27,100 $341,000
Q1 2022 May 11, 2022	SELL	$11.56 - $19.76 $131,784 - $225,264	-11,400 Reduced 24.2%	35,700 $580,000
Q4 2021 Feb 08, 2022	SELL	$11.18 - $15.46 $207,948 - $287,556	-18,600 Reduced 28.31%	47,100 $652,000
Q3 2021 Nov 10, 2021	BUY	$14.21 - $17.65 $88,102 - $109,429	6,200 Added 10.42%	65,700 $944,000
Q2 2021 Aug 03, 2021	BUY	$9.5 - $17.24 $565,250 - $1.03 Million	59,500 New	59,500 $941,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.